Noman Shakeel Niazi1, Efstathios Drampalos2, Natasha Morrissey3, Noman Jahangir4, Alexander Wee5, Anand Pillai6. 1. Trauma and Orthopaedics Department, Wythenshawe Hospital, Manchester University Foundation Trust, United Kingdom. Electronic address: noman.niazi@mft.nhs.uk. 2. Trauma and Orthopaedics Department, Wythenshawe Hospital, Manchester University Foundation Trust, United Kingdom. Electronic address: Efstathios.Drampalos@uhsm.nhs.uk. 3. Trauma and Orthopaedics Department, Frimley Health NHS Foundation Trust, Surrey, United Kingdom. Electronic address: natashamorrissey@doctors.org.uk. 4. Trauma and Orthopaedics Department, Wythenshawe Hospital, Manchester University Foundation Trust, United Kingdom. Electronic address: noman.jahangir@mft.nhs.uk. 5. Trauma and Orthopaedics Department, Frimley Health NHS Foundation Trust, Surrey, United Kingdom. Electronic address: alexander.wee@nhs.net. 6. Trauma and Orthopaedics Department, Wythenshawe Hospital, Manchester University Foundation Trust, United Kingdom. Electronic address: anand.pillai@mft.nhs.uk.
Abstract
BACKGROUND: Diabetic foot ulcers are associated with a high morbidity and are common cause of non-traumatic lower limb amputations. The effect of debridement and the use of an adjuvant local antibiotic carrier in the treatment of diabetic foot ulcers with osteomyelitis was evaluated. METHODS: A retrospective review of patients with diabetic foot ulceration and osteomyelitis treated by debridement with adjuvant local antibiotic was performed. Seventy patients with Texas Grade 3B & 3D lesions were included, with a mean age of 68 years. Cerament G, an antibiotic-loaded absorbable calcium sulphate/hydroxyapatite bio-composite was used along with intraoperative multiple bone sampling and culture-specific systemic antibiotics. RESULTS: Patients were followed up until infection eradication or ulcer healing. Mean follow up was 10 months (4-28months). Nine patients had Charcot foot deformity, 14 had peripheral vascular disease. 62% of patients had forefoot, 5% midfoot and 33% hind foot involvement. Fifty-three patients (87%) had polymicrobial infection. Staphylococcus aureus was the most common microorganism isolated. Infection was eradicated in 63 patients (90%) with mean time to ulcer healing of 12 weeks. Seven patients were not cured and required further treatment. Five patients had below knee amputation. CONCLUSIONS: Adjuvant, local antibiotic therapy with an absorbable bio-composite can help achieve up to 90% cure rates in diabetic foot ulceration with osteomyelitis. Cerament G can act as effective void filler allowing dead space management after excision and preventing reinfection and the need for multiple surgical procedures. LEVEL OF EVIDENCE: Level IV- case series. Crown
BACKGROUND:Diabetic foot ulcers are associated with a high morbidity and are common cause of non-traumatic lower limb amputations. The effect of debridement and the use of an adjuvant local antibiotic carrier in the treatment of diabetic foot ulcers with osteomyelitis was evaluated. METHODS: A retrospective review of patients with diabetic foot ulceration and osteomyelitis treated by debridement with adjuvant local antibiotic was performed. Seventy patients with Texas Grade 3B & 3D lesions were included, with a mean age of 68 years. Cerament G, an antibiotic-loaded absorbable calcium sulphate/hydroxyapatite bio-composite was used along with intraoperative multiple bone sampling and culture-specific systemic antibiotics. RESULTS:Patients were followed up until infection eradication or ulcer healing. Mean follow up was 10 months (4-28months). Nine patients had Charcot foot deformity, 14 had peripheral vascular disease. 62% of patients had forefoot, 5% midfoot and 33% hind foot involvement. Fifty-three patients (87%) had polymicrobial infection. Staphylococcus aureus was the most common microorganism isolated. Infection was eradicated in 63 patients (90%) with mean time to ulcer healing of 12 weeks. Seven patients were not cured and required further treatment. Five patients had below knee amputation. CONCLUSIONS: Adjuvant, local antibiotic therapy with an absorbable bio-composite can help achieve up to 90% cure rates in diabetic foot ulceration with osteomyelitis. Cerament G can act as effective void filler allowing dead space management after excision and preventing reinfection and the need for multiple surgical procedures. LEVEL OF EVIDENCE: Level IV- case series. Crown
Authors: David H Truong; Roger Bedimo; Matthew Malone; Dane K Wukich; Orhan K Oz; Amanda L Killeen; Lawrence A Lavery Journal: Open Forum Infect Dis Date: 2022-08-09 Impact factor: 4.423
Authors: Marcel Niemann; Frank Graef; Sufian S Ahmad; Karl F Braun; Ulrich Stöckle; Andrej Trampuz; Sebastian Meller Journal: Diagnostics (Basel) Date: 2022-05-11
Authors: Kor H Hutting; Wouter B Aan de Stegge; Jaap J van Netten; Wouter A Ten Cate; Luuk Smeets; Gijs M J M Welten; Dick M Scharn; Jean-Paul P M de Vries; Jeff G van Baal Journal: J Clin Med Date: 2021-01-19 Impact factor: 4.241
Authors: Aleksey Dvorzhinskiy; Giorgio Perino; Robert Chojnowski; Marjolein C H van der Meulen; Mathias P G Bostrom; Xu Yang Journal: J Bone Jt Infect Date: 2021-07-20